# A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

> **NCT01807949** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 563 (actual)

## Conditions studied

- Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

## Interventions

- **DRUG:** Placebo
- **DRUG:** Lumacaftor Plus Ivacaftor Combination
- **DRUG:** Ivacaftor

## Key facts

- **NCT ID:** NCT01807949
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 563 (ACTUAL)
- **Last updated:** 2016-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01807949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01807949, "A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01807949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*